Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: F. Andre, J. Baselga, M. J. Ellis, S. A. Hurvitz, H. S. Rugo, N. C. Turner, E. Argonza-Aviles, S. Lake, M. M. Shi, O. Anak
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2590650442